Michael Wirzberger’s period as Etac’s interim CEO will come to an end in January 2020 when his successor Fredrik Dalborg takes over to ‘drive the growth journey’.
Etac is a Swedish equipment manufacturer worth around £150m in sales and serving the UK market with a range of mobility and patient handling products.
Dalborg is currently the CEO of Boule Diagnostics, a blood diagnostics company listed on the Stockholm stock exchange.
Prior to his current role he worked for more than 15 years at Gambro and Terumo BCT, where he held various roles including business development, sales as well as product and business unit management, based out of Sweden, the US, Belgium and Asia.
Nora Larssen, the chair of Etac’s board, said: “The board is convinced that Fredrik Dalborg has a strong background to lead Etac in the next phase of growing the company.
“He has extensive experience from the medtech industry, has worked in a global setting for 20 years based out of Europe as well as the US and Asia and he has solid experience driving growth.”
Dalborg commented: “I am impressed by how Etac systematically has built a position as a strong, global company and I am enthusiastic about the chance to lead a company that develops renowned products for the global mobility and patient handling market.
“I see great opportunities to together with the rest of the Etac team continue to develop the company and drive the growth journey.”